Acute and subchronic oral toxicity studies of hydrogenated curcuminoid formulation ‘CuroWhite’ in rats

Toxicology Reports

Volumn 3, Issue , 2016, Pages 817-825

  Gopi, Sreeraj ^a   Jacob, Joby ^a   Mathur, Kotrappa Y ^b  

^a R and D Centre   (India)

^b Liveon Biolabs Pvt Ltd   (India)

Author keywords

Acute oral toxicity; CuroWhite; Sprague Dawley rats; Subchronic oral toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BETA CYCLODEXTRIN; CREATININE; CURCUMIN; GLUCOSE; HEMOGLOBIN; HYDROGENATED CURCUMINOID; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; LEUKOCYTE COUNT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE COUNT; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN;

EID: 84993991636     PISSN: 22147500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxrep.2016.10.007     Document Type: Article

References (21)

1. [1] Jurenka, J.S., Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of pre-clinical and clinical research. Altern. Med. Rev. 14:2 (2009), 141–153.
2. [2] Aggarwal, B.B., Sundaram, C., Malani, N., Ichikawa, H., Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 595 (2007), 1–75.
3. [3] Rout, K.K., Parida, S., Mishra, S.K., Standardization of the ayurvedic formulation Haridra Khanda using high-performance thin-layer chromatography-densitometry. J. AOAC Int. 91:5 (2008), 1162–1168.
4. [4] Sreeraj, G., Jacob, J., George, R., Sreeraj, T.R., A unique formulation of hydrogenated curcuminoids with higher bio availability and the application in food matrices. J. Nutr. Food Sci. 6:2 (2016), 1–4.
5. [5] Roughley, P.J., Whiting, D.A., Experiments in the biosynthesis of curcumin. J. Chem. Soc. Perkin Trans. 1:20 (1973), 2379–2388.
6. [7] Ireson, C., Orr, S., Jones, D.J., Verschoyle, R., Lim, C.K., Luo, J.L., Howells, L., Plummer, S., Jukes, R., Williams, M., Steward, W.P., Gescher, A., Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61:3 (2001), 1058–1064.
7. [8] Dempe, J.S., Pfeiffer, E., Grimm, A.S., Metzler, M., Metabolism of curcumin and induction of mitotic catastrophe in human cancer cells. Mol. Nutr. Food Res. 52:9 (2008), 1074–1081.
8. [9] Zhao, F., Gong, Y., Hu, Y., Lu, M., Wang, J., Dong, J., Chen, D., Chen, L., Fu, F., Qiu, F., Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide: translocation of nuclear factor-κB as potential target. Mol. Med. Rep. 4 (2015), 3087–3093.
9. [10] Sugiyama, Y., Kawakishi, S., Osawa, T., Involvement of the β-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 52:4 (1996), 519–525.
10. [11] Osawa, T., Sugiyama, Y., Inayoshi, M., Kawakishi, S., Antioxidative activity of tetrahydrocurcuminoids. Biosci. Biotechnol. Biochem. 59:9 (1995), 1609–1612.
11. [12] Murugan, P., Pari, L., Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sci. 79:18 (2006), 1720–1728.
12. [13] Murugan, P., Pari, L., Rao, C.A., Effect of tetrahydrocurcumin on insulin receptor status in type 2 diabetic rats: studies on insulin binding to erythrocytes. J. Biosci. 33:1 (2008), 63–72.
13. [14] Chen, C.Y., Yang, W.L., Kuo, S.Y., Cytotoxic activity and cell cycle analysis of hexahydrocurcumin on SW 480 human colorectal cancer cells. Nat. Prod. Commun. 6:11 (2011), 1671–1672.
14. [15] Dong, H.P., Yang, R.C., Chunag, I.C., Huang, L.J., Li, H.T., Chen, H.L., Chen, C.Y., Inhibitory effect of hexahydrocurcumin on human platelet aggregation. Nat. Prod. Commun. 7:7 (2012), 883–884.
15. [16] Pandher, K., Leach, M.W., Burns-Naas, L.A., Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach. Vet. Pathol. 49:2 (2012), 357–361.
16. [17] Eichenbaum, G., Damsch, S., Looszova, A., Vandenberghe, J., Van den Bulck, K., Roels, K., Megens, A., Knight, E., Hillsamer, V., Feyen, B., Kelley, M.F., Tonelli, A., Lammens, L., Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies. J. Appl. Toxicol. 31:4 (2011), 342–354.
17. [18] Tsokos, M., Forensic Pathology Reviews, vol. 3, 2005, Humana Press Inc., Totowa, NJ (5).
18. [19] Zhong-Ze, H., Hong-De, X., Kwang-Ho, K., Tae-Hwan, A., Jin-Sook, B., Ji-Young, L., Ki-Hyun, G., Joo-Young, L., Su-Jung, W., Hyun-Jung, Y., Hyun-Kul, L., Kap-Ho, K., Chan-Koo, P., Hu-Song, Z., Si-Whan, S., Reference data of the main physiological parameters in control Sprague-Dawley rats from pre-clinical toxicity studies. Lab. Anim. Res. 26:2 (2010), 153–164.
19. [20] Reddy, V.C., Amulya, V., Lakshmi, C.A., Reddy, D.B.P.K., Pratima, D., Thirupathi, A.T., Kumar, K.P., Sengottuvelu, S., Effect of simvastatin in gentamicin induced nephrotoxicity in albino rats. Asian J. Pharm. Clin. Res. 5:1 (2012), 36–40.
20. [21] Osawa, T., Nephroprotective and hepatoprotective effects of curcuminoids. Adv. Exp. Med. Biol. 595 (2007), 407–423.
21. [22] Pan, M.H., Huang, T.M., Lin, J.K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27:4 (1999), 486–494.